Skip to main content

Table 1 IC50 of iMN013 following a single dose of iMN013 and 72 hour incubation, and following redosing every 12 hours x 6 doses

From: iMN041 is an immunotherapeutic and an effective treatment in mouse xenograft models of pancreatic cancer, renal cancer and triple negative breast cancer

Cell Line

IC50 of iMN013 (nM)

72 h Exposure

72 h Exposure

12 h Redosing

12 h Redosing

EMT-6

1.25

1.58

0.22

0.24

4T1

>100

>100

0.24

0.35

DU4475

3.54

3.73

0.09

0.09

MCF-7

15.2

12.3

0.14

0.12

MDA-MB-231

>100

>100

>100

>100

BxPC-3

44

>100

0.23

0.26

CFPAC-1

3.69

3.52

0.10

0.12

MiaPaca-2

8.48

7.81

0.10

0.10

SW1990

1.68

1.57

<0.1

<0.1

Renca

6.1

7.7

0.48

0.55